Bogdan Czerniak

Has grant

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Professor Bogdan Czerniak is a faculty member at The University of Texas MD Anderson Cancer Center, located in the United States. His research focuses on various aspects of bladder cancer, including its variants, molecular profiles, and the progression to aggressive subtypes. He has published extensively on topics such as urethral adenocarcinoma and the effects of mucosal fields in cancer origin.

Recent Grants

Grant: Open

Integrative modeling of spatially resolved multi-omics data to identify bladder cancer mucosal field effects

Open Date: 2023-03-01

Close Date: 2027-02-01

Grant: Close

Monitoring of Field Effects for the Detection of Bladder Cancer

Open Date: 2022-03-01

Close Date: 2026-02-01

Articles (7)

Purpose: Primary urethral adenocarcinoma (PAC) is a rare malignancy associated with poor outcomes. There are 2 primary subtypes—clear cell adenocarcinoma (CCAC) and non–clear cell adenocarcinoma (nCCAC). In this study, we compare oncologic outcomes between CCAC vs nCCAC histological subtypes and describe differences in treatment modalities. Materials and Methods: We performed a retrospective review of patients diagnosed with PAC at our institution between 1993 to 2024. Survival analysis was stratified by histologic subtype (CCAC vs nCCAC) and primary treatment modality. Survival outcomes were stratified by patient age, neoadjuvant therapy (NAT), primary treatment modality, clinical stage, and histological subtype. Results: Of the 35 patients identified, the majority were female, were Black, and presented with locally advanced disease. Most of the patients were treated with radiotherapy (XRT) or surgical extirpation. There were no significant differences in clinical staging or histologic subtype between the 2 treatment modalities. Ten patients were treated with XRT, and 21 patients underwent primary surgical extirpation. Most of the patients received NAT. Locally advanced disease on final pathology was common for both histological subtypes. No patients were downstaged after surgical extirpation, despite nearly all receiving NAT. Survival was significantly better for CCAC vs nCCAC. There was no statistical difference in survival when comparing by treatment modality. Conclusions: PAC represents a rare, aggressive form of cancer. Favorable outcomes among the CCAC cohort may reflect a more favorable disease biology. Despite most of the patients receiving NAT, there were no patients with pathologic downstaging suggesting current neoadjuvant regimens are suboptimal and novel systemic strategies are needed for tumor downstaging to facilitate optimal local tumor control and improved oncologic outcomes.

Year:

2025

Year:

2024

Year:

2024

Multi-platform mutational, proteomic, and metabolomic spatial mapping was used on the whole-organ scale to identify the molecular evolution of bladder cancer from mucosal field effects. We identified complex proteomic and metabolomic dysregulations in microscopically normal areas of bladder mucosa adjacent to dysplasia and carcinoma in situ . The mutational landscape developed in a background of complex defects of protein homeostasis which included dysregulated nucleocytoplasmic transport, splicesome, ribosome biogenesis, and peroxisome. These changes were combined with altered urothelial differentiation which involved lipid metabolism and protein degradations controlled by PPAR. The complex alterations of proteome were accompanied by dysregulation of gluco-lipid energy-related metabolism. The analysis of mutational landscape identified three types of mutations based on their geographic distribution and variant allele frequencies. The most common were low frequency α mutations restricted to individual mucosal samples. The two other groups of mutations were associated with clonal expansion. The first of this group referred to as β mutations occurred at low frequencies across the mucosa. The second of this group called γ mutations increased in frequency with disease progression. Modeling of the mutations revealed that carcinogenesis may span nearly 30 years and can be divided into dormant and progressive phases. The α mutations developed gradually in the dormant phase. The progressive phase lasted approximately five years and was signified by the advent of β mutations, but it was driven by γ mutations which developed during the last 2–3 years of disease progression to invasive cancer. Our study indicates that the understanding of complex alterations involving mucosal microenvironment initiating bladder carcinogenesis can be inferred from the multi-platform whole-organ mapping.

Year:

2024

Year:

2022

Year:

2020

Year:

2020

Collaborators (3)

Sung Yun Jung

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Lauren Colbert

Professor

Duke University

UNITED STATES
View details

Alexandra Callan

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details